Levine Jon R 4

What Happened

• Jon R. Levine, reported as a 10% owner of Marimed, received a grant of 122,500 restricted stock units (RSUs) on April 15, 2026. The award is reported as a derivative acquisition with an acquisition price of $0 in the filing. The RSUs were granted in lieu of cash payment of a portion of Levine’s annual bonus for the fiscal year ended December 31, 2025. These RSUs convert to common stock on a one-for-one basis as they vest.

Key Details

• Transaction date: 2026-04-15; Form 4 filed: 2026-04-17 (filed within the typical two-business-day window).
• Security: 122,500 RSUs (derivative securities), reported acquisition price $0.
• Vesting: Four equal installments vesting on July 15, 2026; October 15, 2026; January 15, 2027; and April 15, 2027.
• Conversion: RSUs convert one-for-one into common stock upon vesting.
• Footnotes: Shares are held in trust for the benefit of the reporting person’s spouse and children; the reporting person disclaims beneficial ownership of those trust-held securities.
• Shares owned after the transaction: Not disclosed in this filing.
• Remark: RSUs were granted in lieu of a cash portion of the fiscal 2025 bonus.

Context

• RSUs are a form of compensation, not an immediate cash purchase or sale. They only become actual shares if and when they vest; value realized will depend on Marimed’s share price at vesting. Such awards are routine compensation disclosures and do not by themselves indicate a buy or sell signal. As a reported 10% owner, Levine is a significant shareholder, but this grant reflects compensation rather than an open-market investment decision.